


AMENDMENT

In the Claims:

✓ ✓ ✓ ✓
Please cancel claims 30, 31 and 46.

Please amend the pending claims as follows:

3. (Thrice Amended) A N¹-monosubstituted polyamine analogue or derivative represented by the formula



wherein R is selected from a D or L amino acid; D or L ornithine, an alicyclic, a single or multi-ring aromatic; aliphatic-substituted single or multi-ring aromatic; and a substituted or unsubstituted, single or multi-ring heterocyclic, and

wherein said analogue or derivative does not have a formula represented by ID 1022, 1043, or 1202.

C²
33.(amended) An analogue or derivative according to claim 3 wherein R is a D or L amino acid or D or L ornithine.

34.(amended) A composition comprising a polyamine analogue or derivative according to claim 3, 32 or 33 and a pharmaceutically acceptable excipient.

C³
38.(amended) A method according to claim 37 wherein said undesired cell proliferation is associated with proliferation of cells of the immune system, cells of the vascular neontima, tumor cells or with undesired angiogenesis.

✓
Please add the following new claims 49-53:

49. (New) The analogue or derivative of claim 3, wherein said substituted or unsubstituted heterocyclic is a pyrrolidine or a substituted pyrrolidine.

50. (New) The analogue or derivative of claim 49, wherein said substituted pyrrolidine is an N-substituted pyrrolidine.

C4 51. (New) The analogue or derivative of claim 50 represented by the formula ID 1158.

52. (New) The analogue or derivative of claim 3 represented by the formula ID 1224.

53. (New) A method according to claim 37 wherein said condition is associated with cancer.
